相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non- small cell lung cancer
Daniel Owen et al.
HUMAN PATHOLOGY (2017)
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
Silvia von Karstedt et al.
NATURE REVIEWS CANCER (2017)
Resistance to HSP90 inhibition involving loss of MCL1 addiction
S. Busacca et al.
ONCOGENE (2016)
MesobanK UK: an international mesothelioma bioresource
Robert C. Rintoul et al.
THORAX (2016)
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
Raphael Bueno et al.
NATURE GENETICS (2016)
Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy
Zhengqiang Yuan et al.
CYTOTHERAPY (2015)
The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer
Salima Daou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
Avi Ashkenazi
JOURNAL OF CLINICAL INVESTIGATION (2015)
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave et al.
NATURE MEDICINE (2015)
Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity
Akihiro Fujimoto et al.
NATURE COMMUNICATIONS (2015)
Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex
Anand Balasubramani et al.
NATURE COMMUNICATIONS (2015)
Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma
Guangwu Guo et al.
CANCER RESEARCH (2015)
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2015)
Germline Mutations in BAP1 Impair Its Function in DNA Double-Strand Break Repair
Ismail Hassan Ismail et al.
CANCER RESEARCH (2014)
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
J. Lemke et al.
CELL DEATH AND DIFFERENTIATION (2014)
Getting TRAIL back on track for cancer therapy
J. Lemke et al.
CELL DEATH AND DIFFERENTIATION (2014)
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer
Joachim von Pawel et al.
CLINICAL LUNG CANCER (2014)
The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex
Zongling Ji et al.
NUCLEIC ACIDS RESEARCH (2014)
Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL
Pamela M. Holland
CANCER LETTERS (2013)
Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells
E. Passante et al.
CELL DEATH AND DIFFERENTIATION (2013)
A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Zev A. Wainberg et al.
CLINICAL COLORECTAL CANCER (2013)
A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer
Andres Forero-Torres et al.
CANCER MEDICINE (2013)
The landscape of cancer genes and mutational processes in breast cancer
Philip J. Stephens et al.
NATURE (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
BAP1 loss defines a new class of renal cell carcinoma
Samuel Pena-LlopiS et al.
NATURE GENETICS (2012)
Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation
Anwesha Dey et al.
SCIENCE (2012)
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew Bott et al.
NATURE GENETICS (2011)
PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data
Chris D. Greenman et al.
BIOSTATISTICS (2010)
Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer
Jean-Charles Soria et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia
J. Boultwood et al.
LEUKEMIA (2010)
Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB
Johanna C. Scheuermann et al.
NATURE (2010)
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
J. William Harbour et al.
SCIENCE (2010)
A novel signaling pathway impact analysis
Adi Laurentiu Tarca et al.
BIOINFORMATICS (2009)
Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads
Kai Ye et al.
BIOINFORMATICS (2009)
The Deubiquitinating Enzyme BAP1 Regulates Cell Growth via Interaction with HCF-1
Yuichi J. Machida et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Association of C-Terminal Ubiquitin Hydrolase BRCA1-Associated Protein 1 with Cell Cycle Regulator Host Cell Factor 1
Shahram Misaghi et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization
Karen H. Ventii et al.
CANCER RESEARCH (2008)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs
TM Ganten et al.
CLINICAL CANCER RESEARCH (2006)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Summaries of affymetrix GeneChip probe level data
RA Irizarry et al.
NUCLEIC ACIDS RESEARCH (2003)
分享论文
